Metabolic profiling of Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) tissue by 1H-NMR analysis: Evidence for unusual phospholipid metabolism

Prostate

Volumn 68, Issue 10, 2008, Pages 1035-1047

  Teichert, Friederike ^a   Verschoyle, Richard D ^a   Greaves, Peter ^a   Edwards, Richard E ^b   Teahan, Orla ^c   Jones, Donald J L ^a   Wilson, Ian D ^d   Farmer, Peter B ^a   Steward, William P ^a   Gant, Timothy W ^b   Gescher, Andreas J ^a   Keim, Hector C ^c  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d ASTRAZENECA   (United Kingdom)

Author keywords

1H NMR analysis; Choline metabolism; Metabolomics; Metabonomics; Prostate cancer

Indexed keywords

CHOLINE; CHOLINE KINASE; CITRIC ACID; GLYCEROPHOSPHORYLCHOLINE; GLYCEROPHOSPHORYLINOSITOL; MESSENGER RNA; PHOSPHOLIPID; PHOSPHORYLCHOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CANCER MODEL; CLUSTER ANALYSIS; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; METABOLITE; METABOLOMICS; MOUSE; NONHUMAN; PHENOTYPE; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; TISSUE LEVEL; TRANSGENIC ADENOCARCINOMA OF THE MOUSE PROSTATE CANCER MODEL; TRANSGENIC MOUSE;

ADENOCARCINOMA; ANIMALS; CHOLINE; CHOLINE KINASE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCERYLPHOSPHORYLCHOLINE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHATIDYLCHOLINES; PHOSPHOLIPIDS; PHOSPHORYLCHOLINE; PROSTATE; PROSTATIC NEOPLASMS; PROTONS; TUMOR MARKERS, BIOLOGICAL;

EID: 45749154849     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20761     Document Type: Article

References (49)

1. Mazhar D, Waxman J. Prostate cancer. Postgrad Med J 2002;78:590-595.
2. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92:3439-3443.
3. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56:4096-4102.
4. Bookstein R, Rio P, Madreperla SA, Hong F, Allred C, Grizzle WE, Lee WH. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 1990;87:7762-7766.
5. Rubin SJ, Hallahan DE, Ashman CR, Brachman DG, Beckett MA, Virudachalam S, Yandell DW, Weichselbaum RR. Two prostate carcinoma cell-lines demonstrate abnormalities in tumor suppressor genes. J Surg Oncol 1991;46:31-36.
6. Verschoyle RD, Greaves P, Cai H, Edwards RE, Steward WP, Gescher AJ. Evaluation of the cancer chemopreventive efficacy of rice bran in genetic mouse models of breast, prostate and intestinal carcinogenesis. Br J Cancer 2007;96:248-254.
7. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 2001;98:10350-10355.
8. Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 2002;62:1370-1376.
9. Morales PR, Dillehay DL, Moody SJ, Pallas DC, Pruett S, Allgood JC, Symolon H, Merrill AH. Safingol toxicology after oral administration to TRAMP mice: Demonstration of safingol uptake and metabolism by N-acylation and n-methylation. Drug Chem Toxicol 2007;30:197-216.
10. Warburg O, Wind F, Negelein E. Ueber den Stoffwechel von Tumoren im Koerper. Klin Wochenschr 1926;5:829-832.
11. Modica-Napolitano JS, Singh KK. Mitochondrial dysfunction in cancer. Mitochondrion 2004;4:755-762.
12. Baggetto LG. Deviant energetic metabolism of glycolytic cancer cells. Biochimie 1992;74:959-974.
13. Costello LC, Franklin RB. 'Why do tumour cells glycolyse?': From glycolysis through citrate to lipogenesis. Mol Cell Biochem 2005;280:1-8.
14. Costello LC, Franklin RB. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: Connecting the dots. Mol Cancer 2006 [Serial on the Internet] 5:17.
15. Glunde K, Serkova NJ. Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics 2006;7:1109-1123.
16. Griffin JL, Kauppinen RA. Tumour metabolomics in animal models of human cancer. J. Proteome Res 2007;6:498-505.
17. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer 2004;4:551-561.
18. Ramírez de Molina A, Rodríguez-González A, Gutiérrez R, Martinez-Pineiro L, Sanchez JJ, Bonilla F, Rosell R, Lacal JC. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002;296:580-583.
19. Al-Saffar NMS, Troy H, Ramirez de Molina A, Jackson LE, Madhu B, Griffiths JR, Leach MO, Workman P, Lacal JC, Judson IR, Chung YL. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res 2006;66:427-434.
20. Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm(3)) spatial resolution. Radiology 1996;198:795-805.
21. Schick F, Bongers H, Kurz S, Jung WI, Pfeffer M, Lutz O. Localized proton MR spectroscopy of citrate in vitro and of the human prostate in vivo at 1.5 T. Magn Reson Med 1993;29:38-43.
22. Cheng LL, Burns MA, Taylor JL, He WL, Halpern EF, McDougal WS, Wu CL. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res 2005;65:3030-3034.
23. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J. United Kingdom Co-Ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 1998;77:1-10.
24. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, Ward JM, Cardiff RD. Prostate pathology of genetically engineered mice: Definitions and classification. The consensus report from the Bar Harbor meeting of the mouse models of human cancer consortium prostate pathology committee. Cancer Res 2004;64:2270-2305.
25. Fan WMT. Metabolite profiling by one- and two-dimensional NMR analysis of complex mixtures. Prog NMR Spectrosc 1996;28:161-219.
26. Nicholson JK, Foxall PJD, Spraul M, Farrant RD, Lindon JC. 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal Chem 1995;67:793-811.
27. Seavey BR, Farr EA, Westler WM, Markley JL. A relational database for sequence-specific protein NMR data. J Biomol NMR 1991;1:217-236.
28. van der Rest B, Boisson AM, Gout E, Bligny R, Douce R. Glycerophosphocholine metabolism in higher plant cells. Evidence of a new glyceryl-phosphodiester phosphodiesterase. Plant Physiol 2002;130:244-255.
29. Dieterle F, Ross A, Schlotterbeck G, Senn H. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. Anal Chem 2006;78:4281-4290.
30. Aoyama C, Ohtani A, Ishidate K. Expression and characterization of the active molecular forms of choline/ethanolamine kinase-alpha and -beta in mouse tissues, including carbon tetrachloride-induced liver. Biochem J 2002;363:777-784.
31. Zhang SD, Gant TW. A statistical framework for the design of microarray experiments and effective detection of differential gene expression. Bioinformatics 2004;20:2821-2828.
32. Swanson MG, Vigneron DB, Tabatabai ZL, Males RG, Schmitt L, Carroll PR, James JK, Hurd RE, Kurhanewicz J. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med 2003;50:944-954.
33. Ramírez de Molina A, Bánez-Coronel M, Gutiérrez R, Rodríguez-González A, Olmeda D, Megías D, Lacal JC. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res 2004;64:6732-6739.
34. Costello LC, Franklin RB. Bioenergetic theory of prostate malignancy. Prostate 1994;25:162-166.
35. Costello LC, Franklin RB. The metabolism of prostate malignancy: Insight into the pathogenesis of prostate cancer and new approaches for its diagnosis and treatment. Oncol Spectr 2001;2:452-457.
36. Fricke ST, Rodriguez O, VanMeter J, Dettin LE, Casimiro M, Chien CD, Newell T, Johnson K, Ileva L, Ojeifo J, Johnson MD, Albanese C. In vivo magnetic resonance volumetric and spectroscopic analysis of mouse prostate cancer models. Prostate 2006;66:708-717.
37. Kurhanewicz J, Dahiya R, MacDonald JM, Chang L-H, James TL, Narayan P. Citrate alterations in primary and metastatic human prostatic adenocarcinomas: 1H magnetic resonance spectroscopy and biochemical study. Magn Reson Med 1993;29:149-157.
38. Kurhanewicz J, Vigneron DB, Nelson SJ. Three-dimensional magnetic resonance imaging of brain and prostate cancer. Neoplasia 2000;2:166-189.
39. Jana S, Blaufox MD. Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med 2006;36:51-72.
40. Alonso T, Morgan RO, Marvizon JC, Zarbl H, Santos E. Malignant transformation by ras and other oncogenes produces common alterations in inositol phospholipid signaling pathways. Proc Natl Acad Sci USA 1988;85:4271-4275.
41. Falasca M, Carvelli A, Iurisci C, Qiu RG, Symons MH, Corda D. Fast receptor-induced formation of glycerophosphoinositol-4-phosphate, a putative novel intracellular messenger in the Ras pathway. Mol Biol Cell 1997;8:443-453.
42. Valitutti S, Cucchi P, Colletta G, Di Filippo C, Corda D. Transformation by the K-ras oncogene correlates with increases in phospholipase A2 activity, glycerophosphoinositol production and phosphoinositide synthesis in thyroid cells. Cell Signal 1991;3:321-332.
43. Buccione R, Baldassarre M, Trapani V, Catalano C, Pompeo A, Brancaccio A, Giavazzi R, Luini A, Corda D. Glycerophosphoinositols inhibit the ability of tumour cells to invade the extracellular matrix. Eur J Cancer 2005;41:470-476.
44. Bensaad K, Tsuruta A, Selak MA, Vidal MNC, Nakano K, Bartrons R, Gottlieb E, Vousden KH. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006;126:107-120.
45. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, Hwang PM. p53 regulates mitochondrial respiration. Science 2006;312:1650-1653.
46. Morgenbesser SD, McLaren RP, Richards B, Zhang M, Akmaev VR, Winter SF, Mineva ND, Kaplan-Lefko PJ, Foster BA, Cook BP, Dufault MR, Cao X, Wang CJ, Teicher BA, Klinger KW, Greenberg NM, Madden SL. Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model. Prostate 2006;67:83-106.
47. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 2004;64:4270-4276.
48. Akech J, Roy SS, Das SK. Modulation of cholinephosphotransferase activity in breast cancer cell lines by Ro5-4864, a peripheral benzodiazepine receptor agonist. Biochem Biophys Res Commun 2005;333:35-41.
49. Ghosh A, Akech J, Mukherjee S, Das SK. Differential expression of cholinephosphotransferase in normal and cancerous human mammary epithelial cells. Biochem Biophys Res Commun 2002;297:1043-1048.